Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Future treatment priorities for high-risk MDS

Yishai Ofran • 5 Mar 2020
MDS 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

Yishai Ofran, MD, Rambam Health Care Campus, Haifa, Israel, discusses the future research priorities in the myelodysplastic syndromes (MDS) field. Specifically, novel agents that decrease the inflammation process within the bone marrow. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Yishai Ofran

1:32
MDS, inflammation and AML
Yishai Ofran • 5 Mar 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals